GlycoMimetics, Inc. :GLYC-US: Earnings Analysis: 2015 By the Numbers

GlycoMimetics, Inc. reports financial results for the year ended December 31, 2015.

We analyze the earnings along side the following peers of GlycoMimetics, Inc. – Tobira Therapeutics, Inc., bluebird bio, Inc., Sanofi Sponsored ADR, Pfizer Inc., Palatin Technologies, Inc. and Johnson & Johnson (TBRA-US, BLUE-US, SNY-US, PFE-US, PTN-US and JNJ-US) that have also reported for this period.


  • Earnings decline largely a result of non-operational activity, pretax margins improved from -74.01% to -63.62%.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2011 2012 2013 2014 2015
Relevant Numbers (Annual)
Revenues 3.81 15.26 3.99 15.03 20.07
Revenue Growth (YOY) N/A N/A N/A N/A N/A
Earnings -6.11 3.66 -10.61 -11.12 -12.77
Earnings Growth (YOY) N/A 159.81 -390.09 -4.87 -14.81
Net Margin -160.29 23.96 -265.63 -74.01 -63.62
EPS -0.55 0.33 -0.57 -0.6 -0.67
Return on Equity -72.29 34.84 -137.42 -41.41 -27.98
Return on Assets -21.15 15.45 -89.49 -35.56 -24.15

Access our Ratings and Scores for GlycoMimetics, Inc.


The company’s earnings decline is largely a result of non-operational activity. As a matter of fact, the company showed increases in operating (EBIT) and pretax margins. EBIT margins improved from -74.13% to -63.69% and pretax margins widened from -74.01% to -63.62%.

EBIT Margin Versus PreTax Margin
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for GlycoMimetics, Inc.

Company Profile

GlycoMimetics, Inc. is a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of GLYC-US.

Leave a Comment